Evidence for disease and antipsychotic medication effects in post-mortem brain from schizophrenia patients

Molecular Psychiatry

Volumn 16, Issue 12, 2011, Pages 1189-1202

  Chan, M K ^a   Tsang, T M ^b   Harris, L W ^a   Guest, P C ^a   Holmes, E ^b   Bahn, S ^a,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

1H NMR; antipsychotic medication; bipolar disorder; LC MS E; post mortem brain; schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; FLUPHENAZINE; GLUTAMINE; MOOD STABILIZER; NEUROLEPTIC AGENT;

ADULT; ARTICLE; AUTOPSY; BIPOLAR DISORDER; COHORT ANALYSIS; FEMALE; GRAY MATTER; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METABOLITE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEOMICS; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA; WESTERN BLOTTING;

ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; BIPOLAR DISORDER; BLOTTING, WESTERN; CHROMATOGRAPHY, LIQUID; DISCRIMINANT ANALYSIS; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; METABOLOMICS; PREFRONTAL CORTEX; PROTEOMICS; SCHIZOPHRENIA;

EID: 81755169872     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2010.100     Document Type: Article

References (104)

1. Ferguson-Smith AC, Greally JM, Martienssen RA. The relevance of epigenetics to major psychosis. Epigenomics. Springer: Netherlands, 2009, pp 411-434.
2. Frith C, Dolan R. The role of the prefrontal cortex in higher cognitive functions. Brain Res Cogn Brain Res 1996; 5: 175-181. (Pubitemid 27095250)
3. Torrey EF, Barci BM, Webster MJ, Bartko JJ, Meador-Woodruff JH, Knable MB. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol Psychiatry 2005; 57: 252-260. (Pubitemid 40187369)
4. Baumann B, Bogerts B. The pathomorphology of schizophrenia and mood disorders: similarities and differences. Schizophr Res 1999; 39: 141-148, discussion 162. (Pubitemid 29415686)
5. Pierri JN, Volk CL, Auh S, Sampson A, Lewis DA. Decreased somal size of deep layer 3 pyramidal neurons in the prefrontal cortex of subjects with schizophrenia. Arch Gen Psychiatry 2001; 58: 466-473. (Pubitemid 32411327)
6. Rosoklija G, Toomayan G, Ellis SP, Keilp J, Mann JJ, Latov N et al. Structural abnormalities of subicular dendrites in subjects with schizophrenia and mood disorders: preliminary findings. Arch Gen Psychiatry 2000; 57: 349-356. (Pubitemid 30202325)
7. Kolluri N, Sun Z, Sampson AR, Lewis DA. Lamina-specific reductions in dendritic spine density in the prefrontal cortex of subjects with schizophrenia. Am J Psychiatry 2005; 162: 1200-1202. (Pubitemid 40770705)
8. Cotter D, Mackay D, Chana G, Beasley C, Landau S, Everall IP. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb Cortex 2002; 12: 386-394. (Pubitemid 34226063)
9. Knable MB, Torrey EF, Webster MJ, Bartko JJ. Multivariate analysis of prefrontal cortical data from the Stanley Foundation Neuropathology Consortium. Brain Res Bull 2001; 55: 651-659. (Pubitemid 32888384)
10. Guidotti A, Auta J, Davis JM, Dong E, Grayson DR, Veldic M et al. GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology (Berl) 2005; 180: 191-205. (Pubitemid 40909664)
11. Beneyto M, Kristiansen LV, Oni-Orisan A, McCullumsmith RE, Meador-Woodruff JH. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 2007; 32: 1888-1902. (Pubitemid 47258508)
12. English JA, Dicker P, Focking M, Dunn MJ, Cotter DR. 2-D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease. Proteomics 2009; 9: 3368-3382.
13. Martins-de-Souza D, Gattaz WF, Schmitt A, Rewerts C, Maccarrone G, Dias-Neto E et al. Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2009; 259: 151-163.
14. Martins-de-Souza D, Gattaz WF, Schmitt A, Maccarrone G, Hunyadi-Gulyas E, Eberlin MN et al. Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J Psychiatr Res 2009; 43: 978-986.
15. Novikova SI, He F, Cutrufello NJ, Lidow MS. Identification of protein biomarkers for schizophrenia and bipolar disorder in the postmortem prefrontal cortex using SELDI-TOF-MS ProteinChip profiling combined with MALDI-TOF-PSD-MS analysis. Neurobiol Dis 2006; 23: 61-76. (Pubitemid 44192384)
16. Pennington K, Beasley CL, Dicker P, Fagan A, English J, Pariante CM et al. Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol Psychiatry 2008; 13: 1102-1117.
17. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 2004; 9: 684-697, 643. (Pubitemid 38932173)
18. Smalla KH, Mikhaylova M, Sahin J, Bernstein HG, Bogerts B, Schmitt A et al. A comparison of the synaptic proteome in human chronic schizophrenia and rat ketamine psychosis suggest that prohibitin is involved in the synaptic pathology of schizophrenia. Mol Psychiatry 2008; 13: 878-896.
19. Behan A, Byrne C, Dunn MJ, Cagney G, Cotter DR. Proteomic analysis of membrane microdomain-associated proteins in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder reveals alterations in LAMP, STXBP1 and BASP1 protein expression. Mol Psychiatry 2009; 14: 601-613.
20. Shao L, Martin MV, Watson SJ, Schatzberg A, Akil H, Myers RM et al. Mitochondrial involvement in psychiatric disorders. Ann Med 2008; 40: 281-295. (Pubitemid 351563935)
21. Khaitovich P, Lockstone HE, Wayland MT, Tsang TM, Jayatilaka SD, Guo AJ et al. Metabolic changes in schizophrenia and human brain evolution. Genome Biol 2008; 9: R124.
22. McLoughlin GA, Ma D, Tsang TM, Jones DN, Cilia J, Hill MD et al. Analyzing the effects of psychotropic drugs on metabolite profiles in rat brain using 1H NMR spectroscopy. J Proteome Res 2009; 8: 1943-1952.
23. Vawter MP, Tomita H, Meng F, Bolstad B, Li J, Evans S et al. Mitochondrial-related gene expression changes are sensitive to agonal-pH state: implications for brain disorders. Mol Psychiatry 2006; 11: 615, 663-679. (Pubitemid 43989805)
24. Li JZ, Vawter MP, Walsh DM, Tomita H, Evans SJ, Choudary PV et al. Systematic changes in gene expression in postmortem human brains associated with tissue pH and terminal medical conditions. Hum Mol Genet 2004; 13: 609-616. (Pubitemid 38379850)
25. Halim ND, Lipska BK, Hyde TM, Deep-Soboslay A, Saylor EM, Herman MM et al. Increased lactate levels and reduced pH in postmortem brains of schizophrenics: Medication confounds. J Neurosci Methods 2008; 169: 208-213.
26. Atz M, Walsh D, Cartagena P, Li J, Evans S, Choudary P et al. Methodological considerations for gene expression profiling of human brain. J Neurosci Methods 2007; 163: 295-309. (Pubitemid 46874608)
27. Cahn W, Hulshoff Pol HE, Lems EB, van Haren NE, Schnack HG, van der Linden JA et al. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch Gen Psychiatry 2002; 59: 1002-1010.
28. Gur RE, Cowell P, Turetsky BI, Gallacher F, Cannon T, Bilker W et al. A follow-up magnetic resonance imaging study of schizophrenia relationship of neuroanatomical changes to clinical and neurobehavioral measures. Arch Gen Psychiatry 1998; 55: 145-152. (Pubitemid 28087600)
29. Berrettini W. Evidence for shared susceptibility in bipolar disorder and schizophrenia. Am J Med Genet C Semin Med Genet 2003; 123C: 59-64. (Pubitemid 37356433)
30. Fritzen S, Lauer M, Schmitt A, Topner T, Strobel A, Lesch KP et al. NO synthase-positive striatal interneurons are decreased in schizophrenia. Eur Neuropsychopharmacol 2007; 17: 595-599. (Pubitemid 47068931)
31. Lan MJ, McLoughlin GA, Griffin JL, Tsang TM, Huang JT, Yuan P et al. Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder. Mol Psychiatry 2009; 14: 269-279.
32. Abdolzade-Bavil A, Hayes S, Goretzki L, Kroger M, Anders J, Hendriks R. Convenient and versatile subcellular extraction procedure that facilitates classical protein expression profiling and functional protein analysis. Proteomics 2004; 4: 1397-1405. (Pubitemid 38648028)
33. Arndt S, Poser I, Schubert T, Moser M, Bosserhoff AK. Cloning and functional characterization of a new Ski homolog, Fussel-18, specifically expressed in neuronal tissues. Lab Invest 2005; 85: 1330-1341. (Pubitemid 41509382)
34. Sabio G, Arthur JS, Kuma Y, Peggie M, Carr J, Murray-Tait V et al. p38gamma regulates the localisation of SAP97 in the cytoskeleton by modulating its interaction with GKAP. EMBO J 2005; 24: 1134-1145. (Pubitemid 40516597)
35. Ma D, Chan MK, Lockstone HE, Pietsch SR, Jones DN, Cilia J et al. Antipsychotic treatment alters protein expression associated with presynaptic function and nervous system development in rat frontal cortex. J Proteome Res 2009; 8: 3284-3297.
36. Hughes MA, Silva JC, Geromanos SJ, Townsend CA. Quantitative proteomic analysis of drug-induced changes in mycobacteria. J Proteome Res 2006; 5: 54-63. (Pubitemid 43100797)
37. Silva JC, Denny R, Dorschel C, Gorenstein MV, Li GZ, Richardson K et al. Simultaneous qualitative and quantitative analysis of the Escherichia coli proteome: a sweet tale. Mol Cell Proteomics 2006; 5: 589-607.
38. Silva JC, Denny R, Dorschel CA, Gorenstein M, Kass IJ, Li GZ et al. Quantitative proteomic analysis by accurate mass retention time pairs. Anal Chem 2005; 77: 2187-2200. (Pubitemid 40463836)
39. Vissers JP, Langridge JI, Aerts JM. Analysis and quantification of diagnostic serum markers and protein signatures for Gaucher disease. Mol Cell Proteomics 2007; 6: 755-766. (Pubitemid 46831929)
40. Schwarz E, Levin Y, Wang L, Leweke FM, Bahn S. Peptide correlation: a means to identify high quality quantitative information in large-scale proteomic studies. J Sep Sci 2007; 30: 2190-2197. (Pubitemid 47497018)
41. Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 2003; 19: 368-375. (Pubitemid 36284936)
42. Eriksson L, Antti H, Gottfries J, Holmes E, Johansson E, Lindgren F et al. Using chemometrics for navigating in the large data sets of genomics, proteomics, and metabonomics (gpm). Anal Bioanal Chem 2004; 380: 419-429.
43. Trygg J, Holmes E, Lundstedt T. Chemometrics in metabonomics. J Proteome Res 2007; 6: 469-479. (Pubitemid 46340151)
44. Hart A. Mann-Whitney test is not just a test of medians: differences in spread can be important. BMJ 2001; 323: 391-393. (Pubitemid 32762474)
45. Park C, Shin KS, Ryu JH, Kang K, Kim J, Ahn H et al. The inhibition of nitric oxide synthase enhances PSA-NCAM expression and CREB phosphorylation in the rat hippocampus. Neuroreport 2004; 15: 231-234. (Pubitemid 38297339)
46. Baba H, Suzuki T, Arai H, Emson PC. Expression of nNOS and soluble guanylate cyclase in schizophrenic brain. Neuroreport 2004; 15: 677-680. (Pubitemid 38457159)
47. Tanda K, Nishi A, Matsuo N, Nakanishi K, Yamasaki N, Sugimoto T et al. Abnormal social behavior, hyperactivity, impaired remote spatial memory, and increased D1-mediated dopaminergic signaling in neuronal nitric oxide synthase knockout mice. Mol Brain 2009; 2: 19.
48. Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001; 50: 884-897. (Pubitemid 34023591)
49. Oshima K, Ruhul Amin AR, Suzuki A, HamaguchiM,Matsuda S. SHPS-1, a multifunctional transmembrane glycoprotein. FEBS Lett 2002; 519: 1-7. (Pubitemid 34521982)
50. Muller D, Mendez P, De Roo M, Klauser P, Steen S, Poglia L. Role of NCAM in spine dynamics and synaptogenesis. Neurochem Res 2008.
51. Rougon G, Hobert O. New insights into the diversity and function of neuronal immunoglobulin superfamily molecules. Annu Rev Neurosci 2003; 26: 207-238. (Pubitemid 37064933)
52. Vawter MP, Cannon-Spoor HE, Hemperly JJ, Hyde TM, Vander-Putten DM, Kleinman JE et al. Abnormal expression of cell recognition molecules in schizophrenia. Exp Neurol 1998; 149: 424-432. (Pubitemid 28115080)
53. Honer WG, Falkai P, Young C, Wang T, Xie J, Bonner J et al. Cingulate cortex synaptic terminal proteins and neural cell adhesion molecule in schizophrenia. Neuroscience 1997; 78: 99-110. (Pubitemid 27132588)
54. Tanaka Y, Yoshida S, Shimada Y, Ueda H, Asai K. Alteration in serum neural cell adhesion molecule in patients of schizophrenia. Hum Psychopharmacol 2007; 22: 97-102. (Pubitemid 46505718)
55. van Kammen DP, Poltorak M, Kelley ME, Yao JK, Gurklis JA, Peters JL et al. Further studies of elevated cerebrospinal fluid neuronal cell adhesion molecule in schizophrenia. Biol Psychiatry 1998; 43: 680-686. (Pubitemid 28222389)
56. Poltorak M, Wright R, Hemperly JJ, Torrey EF, Issa F, Wyatt RJ et al. Monozygotic twins discordant for schizophrenia are discordant for N-CAM and L1 in CSF. Brain Res 1997; 751: 152-154. (Pubitemid 27122148)
57. Vawter MP, Usen N, Thatcher L, Ladenheim B, Zhang P, VanderPutten DM et al. Characterization of human cleaved N-CAM and association with schizophrenia. Exp Neurol 2001; 172: 29-46. (Pubitemid 33141152)
58. Stephan KE, Baldeweg T, Friston KJ. Synaptic plasticity and dysconnection in schizophrenia. Biol Psychiatry 2006; 59: 929-939. (Pubitemid 44288017)
59. Martin KC, Kandel ER. Cell adhesion molecules, CREB, and the formation of new synaptic connections. Neuron 1996; 17: 567-570. (Pubitemid 26365335)
60. Dyck BA, Skoblenick KJ, Castellano JM, Ki K, Thomas N, Mishra RK. Behavioral abnormalities in synapsin II knockout mice implicate a causal factor in schizophrenia. Synapse 2009; 63: 662-672.
61. Chen Q, He G, Qin W, Chen QY, Zhao XZ, Duan SW et al. Family-based association study of synapsin II and schizophrenia. Am J Hum Genet 2004; 75: 873-877. (Pubitemid 39390494)
62. Novak G, Kim D, Seeman P, Tallerico T. Schizophrenia and Nogo: elevated mRNA in cortex, and high prevalence of a homozygous CAA insert. Brain Res Mol Brain Res 2002; 107: 183-189. (Pubitemid 35335536)
63. Johnson RD, Oliver PL, Davies KE. SNARE proteins and schizophrenia: linking synaptic and neurodevelopmental hypotheses. Acta Biochim Pol 2008; 55: 619-628.
64. Sokolov BP, Tcherepanov AA, Haroutunian V, Davis KL. Levels of mRNAs encoding synaptic vesicle and synaptic plasma membrane proteins in the temporal cortex of elderly schizophrenic patients. Biol Psychiatry 2000; 48: 184-196. (Pubitemid 30618990)
65. Halim ND, Weickert CS, McClintock BW, Hyde TM, Weinberger DR, Kleinman JE et al. Presynaptic proteins in the prefrontal cortex of patients with schizophrenia and rats with abnormal prefrontal development. Mol Psychiatry 2003; 8: 797-810. (Pubitemid 37100713)
66. De Waard M, Hering J, Weiss N, Feltz A. How do G proteins directly control neuronal Ca2\+ channel function? Trends Pharmacol Sci 2005; 26: 427-436. (Pubitemid 41039219)
67. Brown DA, Sihra TS. Presynaptic signaling by heterotrimeric G-proteins. Handb Exp Pharmacol 2008; 184: 207-260.
68. Behan AT, Byrne C, Dunn MJ, Cagney G, Cotter DR. Proteomic analysis of membrane microdomain-associated proteins in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder reveals alterations in LAMP, STXBP1 and BASP1 protein expression. Mol Psychiatry 2009; 14: 601-613.
69. Clark D, Dedova I, Cordwell S, Matsumoto I. A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia. Mol Psychiatry 2006; 11: 459-470, 423.
70. Roberts RC, Conley R, Kung L, Peretti FJ, Chute DJ. Reduced striatal spine size in schizophrenia: a postmortem ultrastructural study. Neuroreport 1996; 7: 1214-1218. (Pubitemid 26227042)
71. Harrison PJ. The neuropathology of schizophrenia: a critical review of the data and their interpretation. Brain 1999; 122 (Pt 4): 593-624. (Pubitemid 29158770)
72. Perrone-Bizzozero NI, Sower AC, Bird ED, Benowitz LI, Ivins KJ, Neve RL. Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia. Proc Natl Acad Sci USA 1996; 93: 14182-14187. (Pubitemid 26424266)
73. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 2001; 98: 4746-4751. (Pubitemid 32295047)
74. Martins-de-Souza D, Gattaz WF, Schmitt A, Rewerts C, Marangoni S, Novello JC et al. Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J Neural Transm 2009; 116: 275-289.
75. van Elst LT, Valerius G, Buchert M, Thiel T, Rusch N, Bubl E et al. Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol Psychiatry 2005; 58: 724-730. (Pubitemid 41547240)
76. Bartha R, Williamson PC, Drost DJ, Malla A, Carr TJ, Cortese L et al. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 1997; 54: 959-965. (Pubitemid 28022747)
77. Theberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J et al. Glutamate and glutamine measured with 4.0T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 2002; 159: 1944-1946. (Pubitemid 35283267)
78. Theberge J, Al-Semaan Y, Williamson PC, Menon RS, Neufeld RW, Rajakumar N et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 2003; 160: 2231-2233. (Pubitemid 39619619)
79. Lockwood AH, McDonald JM, Reiman RE, Gelbard AS, Laughlin JS, Duffy TE et al. The dynamics of ammonia metabolism in man. Effects of liver disease and hyperammonemia. J Clin Invest 1979; 63: 449-460. (Pubitemid 9130208)
80. Waagepetersen H, Sonnewald U, Schousboe A. Energy and amino acid neurotransmitter metabolism in astrocytes. Astrocytes in (Patho)Physiology of the Nervous System. Springer: USA, 2009, pp 1-24.
81. Waagepetersen H, Sonnewald U, Schousboe A. Glutamine, glutamate, and GABA: Metabolic aspects. Handbook of Neurochemistry and Molecular Neurobiology. Springer: USA, 2007, pp 1-21.
82. Zoratti M, Szabo I, De Marchi U. Mitochondrial permeability transitions: how many doors to the house? Biochim Biophys Acta 2005; 1706: 40-52. (Pubitemid 40037759)
83. Ongur D, Prescot AP, Jensen JE, Cohen BM, Renshaw PF. Creatine abnormalities in schizophrenia and bipolar disorder. Psychiatry Res 2009; 172: 44-48.
84. Saks VA, Ventura-Clapier R, Aliev MK. Metabolic control and metabolic capacity: two aspects of creatine kinase functioning in the cells. Biochim Biophys Acta 1996; 1274: 81-88. (Pubitemid 26194095)
85. Martins-de-Souza D, Gattaz WF, Schmitt A, Novello JC, Marangoni S, Turck CW et al. Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. BMC Psychiatry 2009; 9: 17.
86. Terao T, Matsuda S, Kojima H, Okuno K, Hori H, Kaku A et al. Incidence and risk factors of benign creatine phosphokinase elevations in chronic psychiatric patients. Neuropsychobiology 1999; 39: 173-180. (Pubitemid 29224862)
87. Klein AM, Ferrante RJ. The Neuroprotective Role of Creatine. Creatine and Creatine Kinase in Health and Disease, vol. 46 Springer: Netherlands, 2007, pp 205-243.
88. Yudkoff M, Daikhin Y, Nissim I, Horyn O, Luhovyy B, Lazarow A. Brain amino acid requirements and toxicity: the example of leucine. J Nutr 2005; 135(6 Suppl): 1531S-1538S. (Pubitemid 40791666)
89. Banos G, Daniel PM, Pratt OE. The effect of age upon the entry of some amino acids into the brain, and their incorporation into cerebral protein. Dev Med Child Neurol 1978; 20: 335-346. (Pubitemid 8348949)
90. Hutson SM, Sweatt AJ, LaNoue KF. Branched chain amino acids (BCAAs) in brain. Handbook of Neurochemistry and Molecular Neurobiology. Springer: USA, 2007, pp 117-131.
91. Bezchlibnyk Y, Young LT. The neurobiology of bipolar disorder: focus on signal transduction pathways and the regulation of gene expression. Can J Psychiatry 2002; 47: 135-148. (Pubitemid 34464555)
92. Vawter MP, Freed WJ, Kleinman JE. Neuropathology of bipolar disorder. Biol Psychiatry 2000; 48: 486-504.
93. Johnston-Wilson NL, Sims CD, Hofmann JP, Anderson L, Shore AD, Torrey EF et al. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol Psychiatry 2000; 5: 142-149. (Pubitemid 30229428)
94. Webster MJ, O'Grady J, Kleinman JE, Weickert CS. Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience 2005; 133: 453-461. (Pubitemid 40726212)
95. Kaiser S, Foltz LA, George CA, Kirkwood SC, Bemis KG, Lin X et al. Phencyclidine-induced changes in rat cortical gene expression identified by microarray analysis: implications for schizophrenia. Neurobiol Dis 2004; 16: 220-235. (Pubitemid 38569813)
96. Ma D, Chan MK, Lockstone HE, Pietsch SR, Jones DN, Cilia J et al. Antipsychotic treatment alters protein expression associated with presynaptic function and nervous system development in rat frontal cortex. J Proteome Res 2009; 8: 3284-3297.
97. Velakoulis D, Wood SJ, Smith DJ, Soulsby B, Brewer W, Leeton L et al. Increased duration of illness is associated with reduced volume in right medial temporal/anterior cingulate grey matter in patients with chronic schizophrenia. Schizophr Res 2002; 57: 43-49.
98. McIntosh AM, Conlon L, Lawrie SM, Stanfield AC. Compliance therapy for schizophrenia. Cochrane Database Syst Rev 2006; 3: CD003442.
99. Honer WG, Falkai P, Bayer TA, Xie J, Hu L, Li HY et al. Abnormalities of SNARE mechanism proteins in anterior frontal cortex in severe mental illness. Cereb Cortex 2002; 12: 349-356. (Pubitemid 34226059)
100. Gabriel SM, Haroutunian V, Powchik P, Honer WG, Davidson M, Davies P et al. Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia. Arch Gen Psychiatry 1997; 54: 559-566. (Pubitemid 27258554)
101. Arion D, Unger T, Lewis DA, Levitt P, Mirnics K. Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol Psychiatry 2007; 62: 711-721. (Pubitemid 47374650)
102. Pennington K, Beasley CL, Dicker P, Fagan A, English J, Pariante CM et al. Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol Psychiatry 2008; 13: 1102-1117.
103. Narayan S, Tang B, Head SR, Gilmartin TJ, Sutcliffe JG, Dean B et al. Molecular profiles of schizophrenia in the CNS at different stages of illness. Brain Res 2008; 1239: 235-248.
104. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003; 362: 798-805. (Pubitemid 37093922)